Literature DB >> 16840726

Hematopoietic origin of fibroblasts/myofibroblasts: Its pathophysiologic implications.

Makio Ogawa1, Amanda C LaRue, Christopher J Drake.   

Abstract

Tissue fibroblasts/myofibroblasts play a key role in growth factor secretion, matrix deposition, and matrix degradation, and therefore are important in many pathologic processes. Regarding the origin of tissue fibroblasts/myofibroblasts, a number of recent in vivo transplantation studies have suggested the bone marrow as the source of fibroblasts/myofibroblasts in liver, intestine, skin, and lung. Because bone marrow cells are thought to contain 2 types of stem cells (ie, hematopoietic stem cells [HSCs] and mesenchymal stem cells), it is important to determine which type of stem cells is the source of fibroblasts/myofibroblasts. To address this issue, we have carried out a series of studies of tissue reconstitution by single HSCs. By transplanting clones derived from single HSCs expressing transgenic enhanced green fluorescent protein, we found that fibroblasts/myofibroblasts in many organs and tissues are derived from HSCs. This brief note summarizes these findings and discusses clinical and experimental perspectives generated by this newly identified differentiation pathway of HSCs.

Mesh:

Substances:

Year:  2006        PMID: 16840726     DOI: 10.1182/blood-2006-04-016600

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

Review 1.  Hematopoietic stem cell origin of mesenchymal cells: opportunity for novel therapeutic approaches.

Authors:  Makio Ogawa; Amanda C Larue; Patricia M Watson; Dennis K Watson
Journal:  Int J Hematol       Date:  2010-03-26       Impact factor: 2.490

Review 2.  Bone marrow mesenchymal stem cells: historical overview and concepts.

Authors:  Pierre Charbord
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

3.  Phylogenetic fate mapping: theoretical and experimental studies applied to the development of mouse fibroblasts.

Authors:  Stephen J Salipante; James M Thompson; Marshall S Horwitz
Journal:  Genetics       Date:  2008-02-03       Impact factor: 4.562

4.  An efficient method for single hematopoietic stem cell engraftment in mice based on cell-cycle dormancy of hematopoietic stem cells.

Authors:  Takanori Abe; Masahiro Masuya; Makio Ogawa
Journal:  Exp Hematol       Date:  2010-03-28       Impact factor: 3.084

5.  Bone Marrow - Home of Versatile Stem Cells.

Authors:  Mariusz Z Ratajczak; Ewa K Zuba-Surma; Wojtek Wojakowski; Janina Ratajczak; Magda Kucia
Journal:  Transfus Med Hemother       Date:  2008-05-08       Impact factor: 3.747

Review 6.  PTH and stem cells.

Authors:  M Ohishi; E Schipani
Journal:  J Endocrinol Invest       Date:  2011-03-22       Impact factor: 4.256

Review 7.  Developmental definition of MSCs: new insights into pending questions.

Authors:  Shishu Huang; Victor Leung; Songlin Peng; Laiching Li; Feng Juan Lu; Ting Wang; William Lu; Kenneth M C Cheung; Guangqian Zhou
Journal:  Cell Reprogram       Date:  2011-09-15       Impact factor: 1.987

Review 8.  Hematopoietic stem cells are pluripotent and not just "hematopoietic".

Authors:  Makio Ogawa; Amanda C LaRue; Meenal Mehrotra
Journal:  Blood Cells Mol Dis       Date:  2013-02-27       Impact factor: 3.039

9.  Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia.

Authors:  Keisuke Shirai; Yasuhiko Sera; William Bulkeley; Meenal Mehrotra; Omar Moussa; Amanda C LaRue; Dennis K Watson; Robert K Stuart; John Lazarchick; Makio Ogawa
Journal:  Exp Hematol       Date:  2009-09-26       Impact factor: 3.084

10.  Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression.

Authors:  Erika L Spaeth; Jennifer L Dembinski; A Kate Sasser; Keri Watson; Ann Klopp; Brett Hall; Michael Andreeff; Frank Marini
Journal:  PLoS One       Date:  2009-04-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.